NMPA (China FDA) Drug Approval: Pathways, Timelines & 2026

What is the NMPA?

The National Medical Products Administration (NMPA) is China’s equivalent of the US Food and Drug Administration (FDA): the national regulator for pharmaceuticals, biological products, medical devices, and cosmetics. Headquartered in Beijing, the NMPA oversees every stage of a drug’s lifecycle — from clinical trial authorization to market approval, post-market surveillance, and manufacturing facility inspections. Its counterparts are the FDA in the US and the European Medicines Agency (EMA) in the EU.

Until 2018, the agency was known as the CFDA — China Food and Drug Administration. In March 2018, the Chinese government restructured the agency under the State Administration for Market Regulation (SAMR), stripping it of food safety oversight and concentrating its mandate entirely on drug and device regulation. The renaming to NMPA reflected this sharper, pharmaceuticals-first focus. For global pharma teams, the distinction between CFDA and NMPA is primarily historical; the NMPA inherited all existing CFDA approvals and institutional relationships.

The NMPA oversees more than 5,000 pharmaceutical manufacturers across China, a figure that underscores both the scale of the market and the regulatory complexity facing overseas companies seeking entry. In practice, foreign pharma teams interact with the NMPA primarily through its Center for Drug Evaluation (CDE) — the technical review body that assesses IND applications, NDAs, and BLAs — and through the Center for Drug Reevaluation (CDR) for post-marketing activities.

Perhaps the most important fact for global pharma strategists to understand is how dramatically the NMPA has transformed over the 2015–2026 period. A decade ago, the agency was characterized internally and externally as slow, opaque, and primarily focused on generic drug equivalence review. The 2015 reform agenda launched by the State Council, followed by China’s ICH membership in 2017, has produced what the industry now recognizes as one of the world’s most aggressively innovator-friendly regulatory agencies. Priority Review timelines, Breakthrough Therapy Designation, and Conditional Approval pathways have made China a genuinely competitive regulatory destination for novel drugs — not merely a large commercial market to enter after FDA and EMA approval.

China’s Pharmaceutical Market Scale

China has the world’s 2nd-largest pharmaceutical market at $163 billion of medicine spending in 2023, trailing only the United States. With an aging population of 1.4 billion and rapidly expanding healthcare coverage, China accounts for approximately 10% of global medicine spending, and IQVIA projects it to exceed $197 billion by 2028.

IQVIA Institute, Global Use of Medicines 2024: Outlook to 2028 (January 2024)

NMPA vs FDA vs EMA: Key Differences

Since China joined the International Council for Harmonisation (ICH) in 2017, the three major global regulatory bodies have moved substantially closer on technical standards. GCP guidelines (E6), statistical principles (E9), and stability testing requirements (Q1) are now largely aligned. Despite this harmonization, meaningful operational differences remain — and understanding them is essential for any cross-border drug development or licensing strategy.

One of the most significant practical advantages of the NMPA pathway is IND review speed and clinical enrollment velocity. China’s population of treatment-naive patients, particularly in oncology and rare disease, enables Phase I and II enrollment that can run two to three times faster than equivalent US or EU sites. For a global pharma company structuring a Multi-Regional Clinical Trial (MRCT), including Chinese sites can compress overall program timelines substantially while simultaneously building the data package needed for an NMPA NDA.

Dimension

NMPA (China)

FDA (USA)

EMA (EU)

IND Review Time

60 working days (implied approval); 30 working days for eligible innovative drugs

30 days (IND takes effect unless placed on clinical hold)

Typically 60 days, up to 106 (EU Clinical Trials Regulation)

NDA/MAA Review

200 working days (standard); 130 working days (priority)

10 months standard; 6 months priority (from filing, for new molecular entities)

210 days (centralized)

Clinical Enrollment Speed

Fastest — large treatment-naive patient pools

Slower — competitive enrollment landscape

Moderate — varies by indication

Foreign Data Acceptance

Accepts ICH-aligned foreign data; prefers MRCT

Accepts MRCT China data; ICH-aligned

Similar to FDA; ICH-aligned

Dossier Language

Chinese (Mandarin) required

English

English (with national translations)

The language requirement is one of the most frequently underestimated operational challenges. Full CTD dossiers — including all clinical study reports, CMC sections, and non-clinical summaries — must be submitted in Mandarin Chinese. For foreign pharma companies without dedicated China regulatory teams, translation quality and terminological accuracy are significant risk factors that can lead to requests for supplementary information (RSI) and timeline delays.

One area where the NMPA has notably converged with FDA and EMA is in its acceptance of MRCT data for simultaneous global submissions. Since 2017, global pharma companies have been able to include Chinese clinical sites in pivotal trials from Phase I onward, eliminating the historical requirement for separate, sequential China-only bridging studies in many indications. This is one of the most commercially significant regulatory shifts of the past decade for cross-border pharma strategy.

NMPA Drug Approval Pathways

The NMPA offers four primary approval pathways for new pharmaceutical products. Pathway selection is one of the most consequential early strategic decisions in a China regulatory program. It affects not only review timelines but also the clinical data package required, the nature of post-approval commitments, and the degree of ongoing CDE interaction during development.

Pathway 1

Standard Review

The baseline pathway for new drug applications that do not qualify for an accelerated designation. Standard Review runs on a review clock of 200 working days from formal acceptance of the dossier; time spent answering supplementary information requests is not counted, so elapsed time is usually longer. This pathway is appropriate for products entering competitive therapeutic areas without an urgent unmet medical need, or for line extensions of approved therapies. Full Phase III pivotal trial data in Chinese or MRCT populations is required.

Pathway 2

Priority Review

Priority Review is granted to drugs addressing rare diseases, pediatric conditions, or representing a significant clinical advance over existing therapies. The target review clock is 130 working days from acceptance (about 6 months, roughly two-thirds of the standard clock), or 70 working days for urgently needed rare disease drugs already approved overseas. To apply, sponsors confirm eligibility with the CDE before filing and submit the Priority Review application together with the NDA, supported by clinical justification. Priority Review status also triggers more frequent CDE feedback opportunities during review.

Pathway 3

Breakthrough Therapy Designation

Reserved for drugs treating life-threatening or seriously debilitating conditions with preliminary clinical evidence of substantial improvement over standard of care. Breakthrough Therapy Designation gives sponsors priority communication with assigned CDE reviewers at key development stages and lets them submit staged clinical data for CDE comment on the next-stage protocol. At the NDA stage, breakthrough drugs can apply for Priority Review. In practice, this is the fastest pathway to market for qualifying oncology and rare disease assets.

Pathway 4

Conditional Approval

Conditional Approval allows market authorization based on surrogate or intermediate endpoints — such as objective response rate (ORR) or progression-free survival (PFS) — from early-phase clinical trials, provided the drug addresses an urgent unmet need. Common in oncology and rare disease. Conditional Approval is granted on the condition that the sponsor completes a confirmatory trial to verify clinical benefit. Failure to fulfill post-market commitments can result in withdrawal of the conditional license.

A critical strategic consideration for the Breakthrough and Priority pathways is the importance of early CDE engagement. Pre-IND consultation meetings (classed by the CDE as Type II meetings) allow sponsors to align on clinical development plans, acceptable endpoints, and CMC expectations before committing to a program design. Companies that invest in this early alignment consistently achieve smoother and faster reviews. For more on how Vision Lifesciences structures parallel FDA/NMPA development programs, see our guide to China biotech licensing opportunities.

IND Application Process in China

The Investigational New Drug (IND) application — known in China as the Clinical Trial Application (CTA) — is the regulatory gateway to conducting human clinical trials in China. Understanding the current IND process is foundational for any global pharma company considering China as part of its clinical development strategy.

The 60-Day to 30-Day Evolution

Prior to the 2018 reforms, China’s IND review operated on a lengthy queue-based system that could take 12–18 months in practice due to a severe backlog at the CDE. In July 2018, the agency adopted an "implied approval" model: if the CDE does not raise objections within 60 working days of accepting an IND, the sponsor may proceed with the trial. The revised Drug Administration Law (2019) and the 2020 Provisions for Drug Registration kept this rule. After a 2024 pilot in Beijing and Shanghai, NMPA Announcement No. 86 of September 2025 added a 30-working-day review nationwide for eligible Class I innovative drugs: key innovative drugs backed by national support policies, pediatric, rare disease and traditional Chinese medicine innovative drugs listed by the CDE, and globally synchronized Phase I/II programs or Phase III multi-regional trials led or co-led by a principal investigator at a Chinese trial site. This brings China’s IND clock for these drugs close to the US FDA’s 30-day review period and is one of the most important operational improvements of the reform era.

In practice, the 60-working-day clock functions well for most straightforward IND applications, and the 30-working-day track requires sponsors to start the trial within 12 weeks of approval. Complex molecules, novel mechanisms of action, or first-in-class biologics may still generate CDE information requests that pause the clock, but the overall velocity of the IND process has improved dramatically relative to pre-2018 conditions.

Required IND Documents

A complete China IND application requires the following core components, structured in CTD format and submitted in Chinese:

Clinical Protocol and Investigator Brochure (IB): Full protocol with statistical design, eligibility criteria, endpoints, and safety monitoring plan. The IB must include all available preclinical and clinical data on the investigational drug.
CMC (Chemistry, Manufacturing and Controls) Data: Drug substance and drug product manufacturing information, analytical specifications, stability data, and batch records. For biologics, additional characterization data is required.
Non-Clinical Safety Data: Pharmacology, pharmacokinetics, and toxicology studies conducted in accordance with ICH S7A/B (safety pharmacology), M3 (toxicology timing), and relevant species selection guidelines.
Phase I Data from Chinese Patients: Historically, China required domestic Phase I bridging data before permitting larger trials. Under the MRCT model now preferred by the NMPA, this requirement can be satisfied by including Chinese sites in global Phase I studies from the outset.

HGRAC Registration: A Mandatory Pre-Trial Step

International clinical trials in China that collect biological samples from Chinese patients — including blood, tissue, or genomic material — need human genetic resources (HGR) approval, or a prior filing where the trial supports a China marketing application and no samples leave the country, before sample collection may begin. HGR oversight has been with the National Health Commission since 1 May 2024 (previously HGRAC under the Ministry of Science and Technology). This requirement is separate from and additional to the NMPA IND process and is one of the most commonly overlooked compliance obligations for foreign sponsors.

NDA/BLA Submission Timeline

Following the completion of pivotal clinical trials, the New Drug Application (NDA) or Biologics License Application (BLA) represents the definitive submission package that triggers NMPA’s formal marketing authorization review. For companies pursuing simultaneous global approvals, optimizing the China NDA timeline alongside FDA and EMA submissions is one of the most complex operational challenges in international regulatory affairs.

CMC Package Requirements

The Chemistry, Manufacturing and Controls (CMC) section of a China NDA is one of the most technically demanding components. The NMPA requires full characterization of the drug substance and drug product manufacturing process, including:

Complete drug substance synthesis or expression/fermentation description with in-process controls
Drug product formulation development history and justification for excipient selection
Validated analytical methods for release and stability testing
At least 12 months of long-term and 6 months of accelerated stability data at ICH Q1A conditions
Container/closure system validation and extractables/leachables assessment for biologics

For foreign manufacturers, the NMPA requires either (a) a China-licensed manufacturing facility, (b) a contract manufacturing arrangement with a China-licensed CMO, or (c) manufacture at an overseas site named in the application. The CDE decides on a risk basis whether to inspect overseas production sites, so an on-site GMP inspection by NMPA inspectors is a logistical consideration that must be planned well in advance of any target NDA submission date.

Clinical Data Requirements

For Standard Review NDAs, the NMPA requires complete Phase III pivotal trial data in Chinese patients or in a MRCT population that includes a sufficient Chinese cohort. For Priority Review and Breakthrough Therapy assets, the CDE will work with sponsors during development to agree on an appropriate pivotal data package, which may include surrogate endpoints in some cases.

Safety databases at NDA submission must be comprehensive, including all clinical trial exposures globally — not just Chinese sites. The NMPA increasingly requests integrated safety summaries (ISS) that present the full global safety profile, consistent with ICH E2F requirements. Ongoing clinical trial safety updates (DSURs) submitted during review must be provided in Chinese and kept current.

Post-Marketing Commitments

For Conditional Approvals, the confirmatory Phase III trial commitment is the central post-marketing obligation and must be specified in the approval conditions. For Priority Review and Breakthrough Therapy approvals, Phase IV surveillance study commitments are standard. The NMPA has strengthened enforcement of post-market commitment timelines in recent years; delays in confirmatory trial enrollment can result in warnings and, in extreme cases, conditional approval withdrawal.

Pre-NDA Meeting Strategy

For Priority Review applications, the single most important risk-mitigation step is securing a Pre-NDA consultation meeting with the CDE before dossier compilation begins. These meetings — classed by the CDE as Type II meetings — allow sponsors to confirm that the clinical data package, CMC strategy, and proposed labeling approach are acceptable to the CDE before investing in the full dossier preparation effort. Companies that skip Pre-NDA meetings frequently receive RSIs (Requests for Supplementary Information) that pause the review clock and can add 6–12 months to the overall approval timeline.

NMPA Reforms: 2017–2026 Timeline

The regulatory transformation of the NMPA over the past decade is one of the most significant shifts in global pharmaceutical regulation. Understanding this reform trajectory — and what it signals about where the agency is heading — is essential context for any long-term China regulatory strategy. For the drugs approved under these rules, see our NMPA approvals tracker.

2017

ICH Membership — Global Harmonization Begins

China joins the International Council for Harmonisation (ICH) as a regulatory member. The CFDA (now NMPA) commits to adopting all ICH guidelines including E6 (GCP), E9 (statistics), Q1A–Q1E (stability), and S-series non-clinical safety guidelines. This single event fundamentally changes the China regulatory landscape, enabling MRCT data acceptance and eventual simultaneous global submissions. In December 2017, the agency also broadens Priority Review to new drugs with significant clinical value.

2018

CFDA Renamed NMPA — Major Restructuring

The State Council restructures the China Food and Drug Administration into the National Medical Products Administration under the State Administration for Market Regulation. Food safety oversight is separated. The NMPA adopts a dual mandate: protecting public health and actively supporting pharmaceutical innovation. In July 2018, implied approval of clinical trial applications is introduced: trials may start if the CDE raises no objection within 60 working days. China also publishes its first national list of 121 rare diseases.

2019

Revised Drug Administration Law

The revised Drug Administration Law, in force from 1 December 2019, writes the reforms into national law: implied approval of clinical trial applications within 60 working days, the nationwide marketing authorization holder (MAH) system, and the legal basis for conditional approval and priority review of urgently needed drugs, including drugs for rare diseases.

2020

New Registration Provisions; Conditional Approval Formalized

The Provisions for Drug Registration take effect on 1 July 2020, setting four expedited pathways — Breakthrough Therapy Designation, Conditional Approval, Priority Review (130 working days, or 70 for urgently needed rare disease drugs approved overseas) and special approval — and keeping 60-working-day implied approval for INDs. The Conditional Approval pathway is formalized through official guidance, specifying eligibility criteria, surrogate endpoint standards, and post-market confirmatory trial requirements. In January 2020, the NMPA also issues its first guideline on using real-world evidence to support drug development and review; a 2021 guideline on real-world data follows, and real-world evidence is increasingly used to support label expansions and post-marketing commitments.

2023

Human Genetic Resources Implementation Rules

Implementation rules for the human genetic resources regulations take effect on 1 July 2023. They streamline approvals and filings for international clinical trials and limit security reviews of data shared with foreign parties to defined cases, such as exome or genome sequencing data covering more than 500 people.

2024–2026

30-Working-Day IND Review; HGR Oversight Moves to the NHC

A 30-working-day review for innovative drug clinical trials is piloted in Beijing and Shanghai from 2024 and extended nationwide by NMPA Announcement No. 86 in September 2025 for eligible Class I innovative drugs, including globally synchronized Phase I/II programs and Phase III multi-regional trials led or co-led by principal investigators at Chinese trial sites. Oversight of human genetic resources moves from the Ministry of Science and Technology to the National Health Commission on 1 May 2024, and the NHC publishes draft revised implementation rules in May 2026. The NMPA continues to deepen MRCT integration, supporting simultaneous submissions alongside FDA and EMA.

The Reform Trend is Structural, Not Cyclical

The NMPA’s shift toward innovation-friendly regulation is embedded in China’s national healthcare strategy (Healthy China 2030). Unlike policy shifts that can reverse with changes in administration, these regulatory reforms are backed by five-year plan commitments and institutional investment in CDE capacity (the CDE grew from fewer than 200 staff in 2014 to more than 800 by 2018). Global pharma companies should plan on a continued trajectory of harmonization and acceleration — not a reversal.

HGRAC: Human Genetic Resources Compliance

China’s human genetic resources (HGR) regime — run by the Human Genetic Resources Administration of China (HGRAC) under the Ministry of Science and Technology (MOST) until 30 April 2024, and by the National Health Commission (NHC) since 1 May 2024 — governs the collection, storage, utilization, and international transfer of Chinese human genetic resources. In the context of pharmaceutical clinical trials, this encompasses biological samples (blood, tissue, saliva), cell lines derived from Chinese donors, and genomic or proteomic data generated from those samples.

HGR compliance is one of the most frequently underestimated and consequentially mismanaged aspects of clinical trial operations in China for foreign sponsors. The 2019 Regulations on the Management of Human Genetic Resources of China set the framework; their 2023 implementing rules narrowed what counts as HGR information (excluding clinical, imaging, protein, and metabolic data) while keeping close scrutiny of genetic data provided to foreign parties.

Core HGRAC Requirements for Clinical Trials

Pre-Trial Registration

International clinical trials in China that collect biological samples from Chinese patients must obtain HGR approval before any sample collection begins, or complete a prior filing where the trial supports a China marketing application and no samples are exported. The application covers the trial protocol, sample collection scope, proposed sample storage and handling plan, and the identity of all parties (domestic and foreign) who will have access to the samples or derived data. Approval decisions are due within 20 working days of acceptance.

Data Export Security Assessment

Providing genomic data, sequencing results, or other human genetic resource data generated from Chinese patients to servers or partners outside China requires a prior report and a backup copy kept in China, unless it is shared within an approved or filed international trial. A formal security review is required for important family pedigrees, data from specific regions, exome or genome sequencing data covering more than 500 people, and other cases affecting public health or national security. The NHC’s May 2026 draft revision of the rules appears to drop this separate security review, but the 2023 rules apply until it is finalized. This applies to data transfers to foreign CROs, foreign biomarker laboratories, and overseas sponsor headquarters. Sponsors must plan HGR reviews into their program timelines — violations carry significant financial penalties and can result in permanent trial suspension.

Sample and Biobank Governance

Long-term biobanking of Chinese patient samples requires ongoing HGR registration maintenance and annual reporting. Any change in the scope of sample use — for example, using banked samples for a new biomarker analysis not specified in the original registration — requires an HGR amendment application. For global sponsors running multi-indication programs from a central biobank, this requires careful governance architecture.

For a comprehensive guide to designing clinical programs that are both NMPA- and HGR-compliant while leveraging China’s clinical enrollment advantages, see our detailed article on China clinical trial advantages for global pharma.

How Vision Lifesciences Navigates NMPA

Navigating the NMPA regulatory environment requires more than a familiarity with published guidelines. The nuances of CDE reviewer preferences, the informal precedents set by recent approvals in a given therapeutic area, and the practical mechanics of HGRAC compliance are known primarily through direct, ongoing engagement with the Chinese regulatory system. Vision Lifesciences provides that institutional knowledge as a dedicated cross-border capability.

Pre-IND Strategy and Dossier Preparation

We work with sponsors from the earliest stages of China program design — including pre-IND meeting strategy, CDE consultation preparation, and technical dossier compilation. Our team includes regulatory affairs professionals with direct CDE interaction experience who understand how to structure IND applications to minimize information request risk and maximize review speed.

Regulatory Timeline Planning for Simultaneous FDA/NMPA Submissions

We design integrated global regulatory timelines that optimize the sequencing of FDA, EMA, and NMPA submissions to maximize patent life and minimize time to revenue in each market. This includes MRCT trial design advisory, bridging study assessment, and rolling submission planning for Breakthrough Therapy assets. Our clients routinely achieve near-simultaneous approvals across all three major markets — a capability that was practically impossible before NMPA’s 2017–2020 reforms.

HGRAC Compliance Structuring

We structure HGRAC registration filings, data export security assessment applications, and ongoing biobank governance frameworks for foreign sponsors conducting clinical programs in China. This includes designing the contractual and technical architecture between foreign sponsors and Chinese clinical sites to ensure HGRAC compliance does not create commercial restrictions on the sponsor’s use of trial data globally.

The intersection of NMPA regulatory strategy and licensing deal structure is where Vision Lifesciences adds the most distinctive value. Whether you are in-licensing a Chinese asset that needs global NDA submissions, or out-licensing a Western molecule into China, regulatory strategy and commercial deal terms are inseparable. Read more about the BioSecure Act’s impact on China pharma partnerships for the geopolitical context shaping deal structures in 2026.

Navigate NMPA drug approval with expert guidance

Our Cross-Border Regulatory Team combines deep NMPA expertise with global commercial strategy — helping you design the right pathway, timeline, and deal structure for your China program.

Frequently Asked Questions

What does NMPA stand for?

NMPA stands for National Medical Products Administration. It is the primary regulatory authority in China responsible for overseeing the safety, efficacy, and quality of drugs, medical devices, and cosmetics — functioning as China’s equivalent to the US FDA or EU EMA.

Is NMPA the same as CFDA?

CFDA (China Food and Drug Administration) was renamed to NMPA (National Medical Products Administration) in 2018 as part of a broader government restructuring. The NMPA took on an expanded regulatory mandate and adopted a more innovation-focused regulatory philosophy, but it is the same underlying regulatory body.

How long does NMPA drug approval take?

NMPA approval timelines vary by pathway. The standard review clock for a marketing application is 200 working days from acceptance. Priority Review shortens it to 130 working days (approximately 6 months) for qualifying drugs such as innovative drugs for rare or major infectious diseases, pediatric drugs, and breakthrough or conditionally approved drugs, and to 70 working days for urgently needed rare disease drugs already approved overseas. Time the sponsor spends answering supplementary information requests is not counted, so elapsed time is usually longer. Breakthrough Therapy drugs can apply for Priority Review when they file.

Does NMPA accept foreign clinical trial data?

Yes. Since joining ICH in 2017, the NMPA increasingly accepts foreign clinical data provided it is generated in accordance with ICH guidelines (E6 GCP, E9 statistics). Multi-Regional Clinical Trial (MRCT) designs that include Chinese sites are strongly preferred. Some therapeutic areas may still require local bridging data demonstrating relevance to Chinese patient populations.

What is the NMPA equivalent in the US?

The US equivalent of China’s NMPA is the Food and Drug Administration (US FDA). Both agencies evaluate drugs for safety, efficacy, and quality before granting market authorization, though they operate under distinct legal frameworks, review timelines, and data requirements. Since 2017, ICH harmonization has brought the two agencies closer on technical standards.

What is a Breakthrough Therapy Designation from NMPA?

NMPA Breakthrough Therapy Designation is an accelerated pathway for innovative drugs treating serious, life-threatening conditions with significant clinical advantages over available therapies. It gives the sponsor priority communication with assigned CDE reviewers at key development stages and lets it submit staged clinical data for CDE comment on the next-stage protocol. At the marketing application stage, breakthrough drugs can apply for Priority Review. This can substantially compress the overall development and review timeline.